The latest price target for National Health Investors (NYSE:NHI) was reported by Truist Securities on December 23, 2024. The analyst firm set a price target for $72.00 expecting NHI to rise to within 12 months (a possible 4.47% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for National Health Investors (NYSE:NHI) was provided by Truist Securities, and National Health Investors maintained their hold rating.

The last upgrade for National Health Investors Inc happened on March 12, 2024 when BMO Capital raised their price target to $67. BMO Capital previously had a market perform for National Health Investors Inc.

The last downgrade for National Health Investors Inc happened on June 21, 2022 when BMO Capital changed their price target from N/A to $62 for National Health Investors Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of National Health Investors, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for National Health Investors was filed on December 23, 2024 so you should expect the next rating to be made available sometime around December 23, 2025.

While ratings are subjective and will change, the latest National Health Investors (NHI) rating was a maintained with a price target of $78.00 to $72.00. The current price National Health Investors (NHI) is trading at is $68.92, which is out of the analyst’s predicted range.